Drug Eluting Technologies in Peripheral Intervention: Why Are They Not as Effective as in the Coronaries and How Do We Get Better?

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Grant Support/Research Contract - Abbott Vascular; Boston Scientific Corporation; Cook Medical; Edwards Lifesciences; Medtronic; NIH-HL141425; 480 Biomedical; 4C Medical; 4Tech; Accumedical; Amgen; Biosensors; Cardiac Implants; Celonova; Claret medical; Comcept Medical; CSI; DuNing, Inc.; Emboline; Endotronix; Envision Scientific; Lutonix Bard; Gateway; Lifetech; Limflo; MedAlliance; Mercator; Merill; Microport Medical; Microvention; Mitraalign; Mitra assist; NAMSA; Nanova; Neovasc; NIPRO; Novogate; Occulotech; OrbusNeich Medical; Phenox; Profusa; Protembis; Qool; ReCor Medical; Senseonics; Shockwave; Sinomed; Spectranetics; Surmodics; Symic; Vesper; Xeltis; Canon U.S.A.; Alivas; Sanofi-Aventis; Leducq Foundation Grant
• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; Boston Scientific Corporation; Cook Medical; Cordis Corporation, a Johnson & Johnson company; Edwards Lifesciences; Medtronic; Terumo Medical Corporation; W.L. Gore & Associates; Celonova; CSI; Lutonix Bard; OrbusNeich Medical; ReCor Medical; Sinomededical Technology; Spectranetics; Surmodics; Xeltis